PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-3.66%
Both yoy net incomes decline, with TRAW at -6.55%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
13.04%
Some D&A expansion while TRAW is negative at -25.00%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
100.00%
Deferred tax of 100.00% while TRAW is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
1.43%
SBC growth of 1.43% while TRAW is zero at 0.00%. Bruce Berkowitz would see some additional share issuance that must be justified by expansions or retention needs.
-401.62%
Both reduce yoy usage, with TRAW at -25.71%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy AP while TRAW is 936.00%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-97.99%
Both reduce yoy usage, with TRAW at -112.96%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-100.00%
Both negative yoy, with TRAW at -395.40%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-93.84%
Both yoy CFO lines are negative, with TRAW at -16.97%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-375.00%
Negative yoy CapEx while TRAW is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-375.00%
We reduce yoy invests while TRAW stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
No Data
No Data available this quarter, please select a different quarter.
-84.27%
Negative yoy issuance while TRAW is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.